THE Therapeutic Goods Administration has published the reasons for the scheduling delegates' final decisions in Jul 2016 relating to a range of amendments to the SUSMP.
Items covered include ulipristal, fexofenadine, 2,4-dinitrophenol, dimethyltrypamine, phenol and piper methysicum (kava), with scheduling changes having an implementation date of 01 Feb 2017.
There are also new chemical entities for human therapeutic use including ocrelizumab and fluxadoline.
See www.tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Oct 16